Shelton Wealth Management LLC Has $892,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Shelton Wealth Management LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 57.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,155 shares of the company’s stock after acquiring an additional 422 shares during the period. Shelton Wealth Management LLC’s holdings in Eli Lilly and Company were worth $892,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. CGN Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 32.9% during the 4th quarter. CGN Advisors LLC now owns 4,199 shares of the company’s stock valued at $3,242,000 after buying an additional 1,040 shares during the last quarter. Sanibel Captiva Trust Company Inc. lifted its stake in Eli Lilly and Company by 20.2% in the fourth quarter. Sanibel Captiva Trust Company Inc. now owns 24,165 shares of the company’s stock valued at $18,655,000 after acquiring an additional 4,065 shares during the last quarter. Howard Financial Services LTD. grew its position in Eli Lilly and Company by 47.0% in the fourth quarter. Howard Financial Services LTD. now owns 632 shares of the company’s stock worth $488,000 after acquiring an additional 202 shares in the last quarter. Integrated Investment Consultants LLC increased its stake in shares of Eli Lilly and Company by 0.3% during the 4th quarter. Integrated Investment Consultants LLC now owns 696,167 shares of the company’s stock worth $537,441,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Arkadios Wealth Advisors raised its holdings in shares of Eli Lilly and Company by 3.2% during the 4th quarter. Arkadios Wealth Advisors now owns 6,748 shares of the company’s stock valued at $5,209,000 after purchasing an additional 207 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 4.1 %

LLY opened at $726.24 on Monday. The company has a market capitalization of $689.43 billion, a P/E ratio of 78.51, a P/E/G ratio of 1.66 and a beta of 0.41. The firm’s fifty day moving average price is $781.14 and its two-hundred day moving average price is $854.35. Eli Lilly and Company has a fifty-two week low of $612.70 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same period in the previous year, the firm posted $0.10 earnings per share. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and Company will post 13.14 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.83%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 64.86%.

Eli Lilly and Company declared that its board has approved a share repurchase program on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on LLY shares. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, January 1st. Wolfe Research began coverage on Eli Lilly and Company in a report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price objective on the stock. Bank of America restated a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Finally, Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,002.22.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.